Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

[A remedy against obesity? The role of lactoferrin in the metabolism of glucose and lipids].

Artym J.

Postepy Hig Med Dosw (Online). 2012 Nov 22;66:937-53. doi: 10.5604/17322693.1021110. Review. Polish.

2.

Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.

Holvoet P.

Verh K Acad Geneeskd Belg. 2008;70(3):193-219. Review.

PMID:
18669160
3.
4.
6.

[Correlations of insulin resistance and neoplasms].

Suba Z, Ujpál M.

Magy Onkol. 2006;50(2):127-35. Epub 2006 Aug 4. Review. Hungarian.

7.

Diabetic dyslipidemia.

Kreisberg RA.

Am J Cardiol. 1998 Dec 17;82(12A):67U-73U; discussion 85U-86U. Review.

PMID:
9915665
8.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
10.

Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.

Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodés-Cabau J, Bertrand OF, Poirier P.

Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1039-49. doi: 10.1161/ATVBAHA.107.159228. Epub 2008 Mar 20. Review. Erratum in: Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):e151.

11.

Effect of GLP-1 based therapies on diabetic dyslipidemia.

Patel VJ, Joharapurkar AA, Shah GB, Jain MR.

Curr Diabetes Rev. 2014;10(4):238-50. Review.

PMID:
24998439
12.

Testosterone: a metabolic hormone in health and disease.

Kelly DM, Jones TH.

J Endocrinol. 2013 Apr 29;217(3):R25-45. doi: 10.1530/JOE-12-0455. Print 2013 Jun. Review.

13.

The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity.

Frigolet ME, Torres N, Tovar AR.

J Nutr Biochem. 2013 Dec;24(12):2003-15. doi: 10.1016/j.jnutbio.2013.07.002. Epub 2013 Oct 9. Review.

PMID:
24120291
14.

The beneficial effects of taurine in preventing metabolic syndrome.

Chen W, Guo J, Zhang Y, Zhang J.

Food Funct. 2016 Apr;7(4):1849-63. doi: 10.1039/c5fo01295c. Review.

PMID:
26918249
15.

Insulin-like growth factor-1 deficiency and metabolic syndrome.

Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I.

J Transl Med. 2016 Jan 6;14:3. doi: 10.1186/s12967-015-0762-z. Review.

16.

Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases.

Scholz GH, Hanefeld M.

Visc Med. 2016 Oct;32(5):319-326. Epub 2016 Oct 7. Review.

PMID:
27921043
17.

Novel nutraceutic therapies for the treatment of metabolic syndrome.

Martínez-Abundis E, Méndez-Del Villar M, Pérez-Rubio KG, Zuñiga LY, Cortez-Navarrete M, Ramírez-Rodriguez A, González-Ortiz M.

World J Diabetes. 2016 Apr 10;7(7):142-52. doi: 10.4239/wjd.v7.i7.142. Review.

18.

Lysophosphatidylinositol Signalling and Metabolic Diseases.

Arifin SA, Falasca M.

Metabolites. 2016 Jan 15;6(1). pii: E6. doi: 10.3390/metabo6010006. Review.

19.

The LDL-receptor family. Lactoferrin and lipid metabolism.

Huettinger M, Meilinger M, Gschwentner C, Lassmann H.

Adv Exp Med Biol. 1998;443:107-11. Review. No abstract available.

PMID:
9781349
20.

Medohara and Lekhaniya dravyas (anti-obesity and hypolipidemic drugs) in Ayurvedic classics: A critical review.

Kumari H, Pushpan R, Nishteswar K.

Ayu. 2013 Jan;34(1):11-6. doi: 10.4103/0974-8520.115437. Review.

Supplemental Content

Support Center